Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.

@article{Fischl2007RandomizedOT,
  title={Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.},
  author={Margaret A Fischl and Ann C Collier and Abir L Mukherjee and Judith E. Feinberg and Lisa M. Demeter and Pablo Tebas and Marina Giuliano and Marjorie Dehlinger and Kevin W Garren and Barbara Brizz and Roland Bassett},
  journal={AIDS},
  year={2007},
  volume={21 3},
  pages={325-33}
}
OBJECTIVES Complex antiretroviral regimens can be associated with increased toxicity and poor adherence. Our aim was to compare the efficacy and safety of switching to two simplified, class-sparing antiretroviral regimens. METHODS We conducted a randomized, open-label study in 236 patients with virologic suppression who were taking a three- or four-drug protease inhibitor or non-nucleoside reverse transcriptase inhibitor regimen for > or = 18 months. Patients received lopinavir/ritonavir (LPV… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review

Therapeutics and clinical risk management • 2008
View 1 Excerpt
Highly Influenced

Similar Papers

Loading similar papers…